We offer our registered users tailored information, free online courses and exclusive content.
Reset it here.
We offer our registered users tailored information, free online courses and exclusive content.
EXCEMED, in collaboration with the European Charcot Foundation (ECF) and AcademicCME, is planning a Virtual Course to be held prior to ECTRIMS-ACTRIMS Congress.
This live, Online Programme will take place from 8am to 11.30am (EST), on both 9th & 10th September, 2020. International experts will address the main scientific breakthroughs in the field and will provide practical suggestions for managing patients in clinical practice.
As the ACTRIMS-ECTRIMS Congress is going Virtual, we are converting the course into a Distance Learning Interactive Programme.
Even more in these circumstances, EXCEMED wants to keep its tradition of high value education and strongly believes that keeping in touch with experts and learners is the basis of ongoing growth and innovation.
The Foundation aims to keep its tradition of Pre-ECTRIMS Educational activities and, even more so, in 2020. Thanks to the partnership with the ECF and Academic CME, plans to offer remote attendees a deeper and more comprehensive learning experience in this field, has been made possible.
This is intended to be a multi-sponsor educational project, supported by a number of companies active in the neurodegenerative diseases/MS field.
Increasing knowledge on the pathogenesis of Multiple Sclerosis (MS) has led to the development of new treatment strategies and novel prognostic biomarkers. Progressive MS, which has always been considered an ‘orphan’ disease, is starting to be treated with disease modifying therapies; neuroprotective and remyelinating strategies are under investigation with the aim of promoting and preserving neuronal health. New measures suitable to establish the true effectiveness of these new therapeutic approaches are required and are currently tested in clinical trials. This course aims to provide updated scientific insights on the world of contemporary MS.
The virtual course aims to achieve the following learning objectives:
Describe new pathogenetic mechanisms involved in MS and NMOS development
Illustrate mechanisms of action and safety profile of new MS treatments
Debate promising novel approaches to quantify MS activity
Joint Accreditation Standards for Commercial Support
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this live material for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Virtual Live-Streamed Pre-ACTRIMS/ECTRIMS 2020 Multiple Sclerosis Curriculum has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Virtual Module I
8:00 am – 8:20 am How Genes and Environment Interact to Cause MS
Alberto Ascherio, MD
8:20 am – 8:40 am NMOSD
Kazuo Fujihara, MD
8:40 am – 9:00 am OCT and Neurofilaments in Clinical Practice
Peter Calabresi, MD
9:00 am – 9:30 am Faculty Discussion Q & A
9:30 am – 9:50 am Standard MRI to Monitor Disease Courses and Treatment Response
Douglas L. Arnold, MD
9:50 am – 10:10 am Advanced MRI to Monitor Disease Courses and Treatment Response
Nicola De Stefano
10:10 am – 10:30 am The Spectrum of Treatments in RMS
Giancarlo Comi, MD, PhD
10:30 am – 10:50 am Enhancing Remyelination: From Basic Studies to Interventions
Hans-Peter Hartung, MD, PhD
10.50 am -11.10 am New Perspectives in Neurorehabilitation
Letizia Leocani, MD, PhD
11.10 am – 11:30 am Faculty Discussion Q & A and Conclusion
Virtual Module II
8:00 am – 8:20 am Understanding Progressive MS
Fred D. Lublin, MD
8:20 am – 8:40 am Treatment Decisions in PMS
Per Soelberg Sorensen, MD
8:40 am – 9:00 am Neuroprotective Treatments
Giancarlo Comi, MD, PhD
9:00 am – 9:30 am Faculty Discussion Q & A
9:30 am – 9:50 am Are We Any Closer to Understanding the Cause of MS?
Peter Calabresi, MD
9:50 am – 10:10 am Electronic Data Capture/Devices - Can We Quantitate Disease Activity?
Jeffrey Cohen, MD
10:10 am – 10:30 am Is it Time to Consider Combination/Add-On Therapies?
Fred D. Lublin, MD
10:30 am – 10:50 am Are We Paying Enough Attention to Safety?
Hans-Peter Hartung, MD, PhD
10:50 am – 11:30 am Faculty Discussion Q & A and Conclusion